Washington University School Of Medicine In St Louis

The transition from primarily chemotherapy-based approaches to targeted therapies revolutionized treatment of chronic lymphocytic leukemia, the most common adult lymphoproliferative disorder in the U.S.

Researchers at Washington University School of Medicine in St. Louis have identified distinct molecular signatures of glioblastoma that may explain differences in treatment responses and survival between men and women.

The upcoming American College of Cardiology Scientific Session will span important topics in the field of cardiology, featuring presentations on atrial fibrillation, updates in HF and even physician burnout, according to a web briefing held by the ACC.

SAN FRANCISCO — Adding adjuvant chemotherapy to postoperative radiotherapy improved DFS and OS among patients with locally advanced bladder cancer after radical cystectomy, according to results of a randomized phase 3 study presented at Genitourinary Cancers Symposium.

DALLAS — Although treatment of femoroacetabular impingement has historically been performed through an open surgical hip dislocation procedure, arthroscopic treatment has now emerged as the dominant surgical approach.

SAN DIEGO — Use of adjuvant low-dose rituximab with plasma exchange reduced incidence of exacerbation and refractory disease among patients with acquired thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency, according to study results presented at ASH Annual Meeting and Exposition.

A study in The Spine Journal recently looked at spinal manipulation and mobilization to manage chronic low back pain and its findings were met with mixed reactions. Orthopedics Today invited spine specialists to discuss the study and similar issues raised in a Forbes article published about the same time.

Researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis have used gene editing technology known as CRISPR to engineer human T cells to attack certain cancers.

Patients with relapsed or refractory acute lymphoblastic leukemia may benefit from a novel fratricide-resistant chimeric antigen receptor T-cell therapy approach, according to study results.

ATLANTA — Maintenance rituximab following first-line bendamustine and rituximab significantly improved PFS, with a trend toward improved OS, among patients with follicular lymphoma, according to a retrospective analysis of the BRIGHT trial presented at the ASH Annual Meeting and Exposition.